Ulrik Ralfkiaer

Ulrik Ralfkiaer

Auto-generated profile, based on publicly available information

Ulrik Ralfkiaer

Department of Hematology, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2011 in Blood
Verified
Journal Article
Open access
PDF file
URUlrik Ralfkiaer
Ulrik Ralfkiaer
PHPeter H. Hagedorn
Peter H. Hagedorn
NBNannie Bangsgaard
Nannie Bangsgaard
MLMarianne Bengtson Løvendorf
Marianne Bengtson Løvendorf
CACharlotte B. Ahler
Charlotte B. Ahler
Niels OdumNiels Odum
Niels Odum
Cutaneous T-cell lymphomas (CTCLs) are the most frequent primary skin lymphomas. Nevertheless, diagnosis of early disease has proven difficult because of a clinical and histologic resemblance to benign inflammatory skin diseases. To address whether microRNA (miRNA) profiling can discriminate CTCL from benign inflammation, we studied miRNA expression levels in 198 patients with CTCL, peripheral T-cell lymphoma (PTL), and benign skin diseases (psoriasis and dermatitis). Using microarrays, we show that the most induced (miR-326, miR-663b, and miR-711) and repressed (miR-203 and miR-205) miRNAs distinguish CTCL from benign skin diseases with > 90% accuracy in a training set of 90 samples and a test set of 58 blinded samples. These miRNAs also distinguish malignant and benign lesions in an independent set of 50 patients with PTL and skin inflammation and in experimental human xenograft mouse models of psoriasis and CTCL. Quantitative (q)RT-PCR analysis of 103 patients with CTCL and benign skin disorders validates differential expression of 4 of the 5 miRNAs and confirms previous reports on miR-155 in CTCL. A qRT-PCR–based classifier consisting of miR-155, miR-203, and miR-205 distinguishes CTCL from benign disorders with high specificity and sensitivity, and with a classification accuracy of 95%, indicating that miRNAs have a high diagnostic potential in CTCL.

5 July 2013 in Haematologica
Verified
Journal Article
Open access
PDF file
FAF. Asmar
F. Asmar
VPV. Punj
V. Punj
JCJ. Christensen
J. Christensen
MPM. T. Pedersen
M. T. Pedersen
APA. Pedersen
A. Pedersen
KGK. Gronbaek
K. Gronbaek
The discovery that the Ten-Eleven Translocation (TET) hydroxylases cause DNA demethylation has fundamentally changed the notion of how DNA methylation is regulated. Clonal analysis of the hematopoetic stem cell compartment suggests that TET2 mutations can be early events in hematologic cancers and recent investigations have shown TET2 mutations in diffuse large B-cell lymphoma. However, the detection rates and the types of TET2 mutations vary, and the relation to global methylation patterns has not been investigated. Here, we show TET2 mutations in 12 of 100 diffuse large B-cell lymphomas with 7% carrying loss-of-function and 5% carrying missense mutations. Genome-wide methylation profiling using 450K Illumina arrays identified 315 differentially methylated genes between TET2 mutated and TET2 wild-type cases. TET2 mutations are primarily associated with hypermethylation within CpG islands (70%; P <0.0001), and at CpG-rich promoters (60%; P <0.0001) of genes involved in hematopoietic differentiation and cellular development. Hypermethylated loci in TET2 mutated samples overlap with the bivalent (H3K27me3/H3K4me3) silencing mark in human embryonic stem cells ( P =1.5×10−30). Surprisingly, gene expression profiling showed that only 11% of the hypermethylated genes were down-regulated, among which there were several genes previously suggested to be tumor suppressors. A meta-analysis suggested that the 35 hypermethylated and down-regulated genes are associated with the activated B-cell-like type of diffuse large B-cell lymphoma in other studies. In conclusion, our data suggest that TET2 mutations may cause aberrant methylation mainly of genes involved in hematopoietic development, which are silenced but poised for activation in human embryonic stem cells.

15 June 2013 in Cell Cycle
Verified
Journal Article
Open access
PDF file
KKKatharina L. Kopp
Katharina L. Kopp
URUlrik Ralfkiaer
Ulrik Ralfkiaer
Lise Mette Rahbek GjerdrumLise Mette Rahbek Gjerdrum
Lise Mette Rahbek Gjerdrum
RHRikke Helvad
Rikke Helvad
IPIda H. Pedersen
Ida H. Pedersen
AWAnders Woetmann
Anders Woetmann
The pathogenesis of cutaneous T-cell lymphoma (CTCL) remains elusive. Recent discoveries indicate that the oncogenic microRNA miR-155 is overexpressed in affected skin from CTCL patients. Here, we address what drives the expression of miR-155 and investigate its role in the pathogenesis of CTCL. We show that malignant T cells constitutively express high levels of miR-155 and its host gene BIC (B cell integration cluster). Using ChIP-seq, we identify BIC as a target of transcription factor STAT5, which is aberrantly activated in malignant T cells and induced by IL-2/IL-15 in non-malignant T cells. Incubation with JAK inhibitor or siRNA-mediated knockdown of STAT5 decreases BIC/miR-155 expression, whereas IL-2 and IL-15 increase their expression in cell lines and primary cells. In contrast, knockdown of STAT3 has no effect, and BIC is not a transcriptional target of STAT3, indicating that regulation of BIC/miR-155 expression by STAT5 is highly specific. Malignant proliferation is significantly inhibited by an antisense-miR-155 as well as by knockdown of STAT5 and BIC. In conclusion, we provide the first evidence that STAT5 drives expression of oncogenic BIC/miR-155 in cancer. Moreover, our data indicate that the STAT5/BIC/miR-155 pathway promotes proliferation of malignant T cells, and therefore is a putative target for therapy in CTCL.

16 May 2008 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
RGRebeqa Gunnarsson
Rebeqa Gunnarsson
JSJohan Staaf
Johan Staaf
MJMattias Jansson
Mattias Jansson
AOAnne Marie Ottesen
Anne Marie Ottesen
HGHanna Göransson
Hanna Göransson
RRRichard Rosenquist
Richard Rosenquist

1 June 2011 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
TKThorbjørn Krejsgaard
Thorbjørn Krejsgaard
URUlrik Ralfkiaer
Ulrik Ralfkiaer
ECErik Clasen-Linde
Erik Clasen-Linde
KEKarsten W. Eriksen
Karsten W. Eriksen
KKKatharina L. Kopp
Katharina L. Kopp
NONiels Odum
Niels Odum

7 September 2010 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
RSReza R. Serizawa
Reza R. Serizawa
URUlrik Ralfkiær
Ulrik Ralfkiær
KSKenneth Steven
Kenneth Steven
GLGitte W. Lam
Gitte W. Lam
SSSven Schmiedel
Sven Schmiedel
PGPer Guldberg
Per Guldberg
The bladder cancer genome harbors numerous oncogenic mutations and aberrantly methylated gene promoters. The aim of our study was to generate a profile of these alterations and investigate their use as biomarkers in urine sediments for noninvasive detection of bladder cancer. We systematically screened FGFR3, PIK3CA, TP53, HRAS, NRAS and KRAS for mutations and quantitatively assessed the methylation status of APC, ARF, DBC1, INK4A, RARB, RASSF1A, SFRP1, SFRP2, SFRP4, SFRP5 and WIF1 in a prospective series of tumor biopsies (N = 105) and urine samples (N = 113) from 118 bladder tumor patients. We also analyzed urine samples from 33 patients with noncancerous urinary lesions. A total of 95 oncogenic mutations and 189 hypermethylation events were detected in the 105 tumor biopsies. The total panel of markers provided a sensitivity of 93%, whereas mutation and methylation markers alone provided sensitivities of 72% and 70%, respectively. In urine samples, the sensitivity was 70% for all markers, 50% for mutation markers and 52% for methylation markers. FGFR3 mutations occurred more frequently in tumors with no methylation events than in tumors with one or more methylation events (78% vs. 33%; p < 0.0001). FGFR3 mutation in combination with three methylation markers (APC, RASSF1A and SFRP2) provided a sensitivity of 90% in tumors and 62% in urine with 100% specificity. These results suggest an inverse correlation between FGFR3 mutations and hypermethylation events, which may be used to improve noninvasive, DNA‐based detection of bladder cancer.